CF PharmTech, Inc. (HKG:2652)

Market Cap	14.42B
Revenue (ttm)	647.51M
Net Income (ttm)	29.75M
Shares Out	411.98M
EPS (ttm)	0.08
PE Ratio	484.62
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,000
Average Volume	264,404
Open	35.40
Previous Close	35.00
Day's Range	34.00 - 35.28
52-Week Range	27.20 - 48.80
Beta	n/a
RSI	49.69
Earnings Date	n/a

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 574
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2652

Financial Performance

In 2024, CF PharmTech's revenue was 607.75 million, an increase of 9.23% compared to the previous year's 556.42 million. Earnings were 21.09 million, a decrease of -33.53%.

Financial numbers in CNY